00:00 Speaker A

I’m just so continued to be so fascinated by the whole obesity I mean this it it feels like such a big cultural moment and we’re still in the midst of it.

00:10 Speaker B

Early days.

00:11 Speaker A

Early days of it. Early days. So what, like, and and in that context it’s also interesting to me that Novo isn’t doing better because culturally it’s so big, you would think that it automatically it would sort of be a big

00:25 Speaker B

Well, Novo’s not doing better because of things that have happened in the past couple of years. Remember, they didn’t have, you know, enough product for Wegovy. They couldn’t supply the market. They were slow to act on DTC. Lilly Direct came months ahead of Novo Care. Right. Um, they didn’t lower their prices quickly as Lilly did. There was a point in time where Zepbound cash pay was less than Wegovy and basically, based on what I said, with the higher efficacy and the better price, that’s where patients went. So they had to make those adjustments. And now they’re putting together a portfolio where they can compete with Zepbound, um with high dose sema, with Amireton, for example, but they’re playing catchup still. Yes, the Wegovy pill is doing wonderfully and yes, Mike is right, he’s dusted off his jacket and he’s, you know, really leaned in.

01:27 Speaker B

But we need to see pull through outside of the United States. We need to see more products, and I need to see a consistent strategy, you know, being developed for the next five years and beyond.

01:42 Speaker A

This has been a two-horse race.

01:43 Speaker B

Sure.

01:44 Speaker A

Who’s the the next horse?

01:46 Speaker B

So, Pfizer’s trying to make a foray. Remember they were Met Sarah, they were bidding against Nova Nordis. That was a wild time back in November. They’re going to have some data at the ADA meeting in June, which is going to be a hot meeting. This is the American Diabetes Association scientific sessions.

02:04 Speaker A

Mark your calendars.

02:05 Speaker B

Mark your calendars. I’ll be there, so I’ll give you all the the the lowdown. But you’re going to get data from Met Sara, um or Pfizer. I think Lilly and Novo also have some data. I forget exactly what they have. But Pfizer’s probably kind of up there. You have Roche, my small cap structure that we’ve talked a lot about. They just announced yesterday that they’re moving into a phase two trial. So, there are other players, a lot of folks are trying to get in. What I say is that if you want to be competitive, you have to have some differentiation.